Back to Search
FORREST GILES, DO
DO
Adult Medicine Physician
NPI: 1558909879Individual
Specialties, Licenses & Credentials
Adult Medicine PhysicianPrimary
Family Medicine — Adult Medicine
Code: 207QA0505X
C8289(TX)
Research & Publications (20)
New directions in the treatment of imatinib failure and/or resistance.
PMID 19621547·Semin Hematol·2009
8-other
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
PMID 19474800·Leukemia·2009
6-review
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
PMID 18346528·Semin Oncol·2008
6-review
Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.
PMID 17892367·Expert Rev Mol Diagn·2007
6-review
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML.
PMID 17577766·Leuk Lymphoma·2007
7-preclinical
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
PMID 17560285·Leuk Res·2007
3-trial
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
PMID 17223919·Br J Haematol·2007
8-other
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
PMID 17146105·J Clin Oncol·2007
3-trial
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
PMID 16990603·Blood·2007
5-case
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
PMID 16332390·Leuk Res·2006
3-trial
Mammalian target of rapamycin as a therapeutic target in leukemia.
PMID 16305491·Curr Mol Med·2005
6-review
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
PMID 15973664·Cancer·2005
8-other
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
PMID 15863204·Leuk Res·2005
3-trial
Accelerated and blastic phases of chronic myelogenous leukemia.
PMID 15271404·Hematol Oncol Clin North Am·2004
6-review
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
PMID 15120936·Leuk Res·2004
4-observational
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy.
PMID 15120931·Leuk Res·2004
3-trial
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
PMID 15109534·Leuk Res·2004
3-trial
Novel therapies for patients with chronic myeloid leukemia.
PMID 15056057·Expert Rev Anticancer Ther·2004
6-review
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
PMID 14632776·Br J Haematol·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 152 MCVOID RD
SPRINGTOWN, TX 76082 - Phone
- (817) 677-3043
Quick Facts
- NPI
- 1558909879
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile